

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : LIDDLE, John
Filing No. : 10/561,498
Filing Date : December 19, 2005
Title : *Substituted Diketopiperazines as Oxytocin Antagonists*

Group / Art Unit : 1612
Examiner : QAZI, Sabiha Naim

Confirmation No. : 6334

Docket No. : PB60330US

MAIL STOP APPEAL BRIEF – PATENTS
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

COMMUNICATION

Sir:

Upon review of the present application, it has come to the Applicant's attention that the Experimental Section contains certain minor errors. The purpose of the present communication is to identify these errors and provide the appropriate corrections for the record. Please see the attached Remarks.

Remarks begin on page 2 of this paper.

REMARKS

The Applicant wishes to make of record a short list of minor corrections in the Experimental Section of the above-referenced application of record. Specifically, the Experimental Section of the present application contains some errors that relate to the amounts of materials employed in the reactions and certain details relating to the exact purification methods used. A table describing the nature of each error and providing the appropriate correction is shown below:

Location of error in specification	Current experimental description	Correct experimental description
Page 10, line 18	(5.0g)	(8.18g)
Page 11, line 7-8	. . . and evaporated. The crude product was and evaporated to give 39.24g of crude product. A small sample of the crude product (1/20 th of total) was . . .
Page 11, line 11	(11.8g 51%)	(1.18g estimated yield ~100%)
Page 11, line 27	(11.8 g pre-dried in vacuo over P ₄ O ₁₀ for 24 hours)	(1g of crude product above, estimated to contain 590 mg of required material)
Page 12, line 9	(0,355 mg, 73%)	(355mg, 73%)
Page 12, line 29	The residue was purified by preparative HPLC to give . . .	The residue was first purified on silica eluting with EtOAc/MeOH or EtOAc/EtOH mixtures, followed by purification by preparative HPLC to give . . .

Application No.: 10/561,498
Attorney Docket No.: PB60330

Should the Examiner have any questions regarding the foregoing, Applicant respectfully requests that the Examiner contact the undersigned, who can be reached at (919) 483-1467.

Respectfully submitted,

/Kathryn L. Coulter/

Kathryn L. Coulter
Attorney for Applicant
Reg. No. 45,889

Date: 12/7/2010
Customer No. 23347
GlaxoSmithKline
Global Patents
Five Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-1467
Facsimile: (919) 483-7988